ABSTRACT
The pressing need for better drugs against Chagas disease, African sleeping sickness, and schistosomiasis motivates the search for inhibitors of cruzain, rhodesain, and
Schistosoma mansoni
CB1 (SmCB1), the major cysteine proteases from
Trypanosoma cruzi
,
Trypanosoma brucei
, and
S. mansoni
, respectively. Thiosemicarbazones and heterocyclic analogues have been shown to be both antitrypanocidal and inhibitory against parasite cysteine proteases. A series of compounds was synthesized and evaluated against cruzain, rhodesain, and SmCB1 through biochemical assays to determine their potency and structure-activity relationships (SAR). This approach led to the discovery of 6 rhodesain, 4 cruzain, and 5 SmCB1 inhibitors with 50% inhibitory concentrations (IC
50
s) of ≤10 μM. Among the compounds tested, the thiosemicarbazone derivative of peracetylated galactoside (compound 4i) was discovered to be a potent rhodesain inhibitor (IC
50
= 1.2 ± 1.0 μM). The impact of a range of modifications was determined; removal of thiosemicarbazone or its replacement by semicarbazone resulted in virtually inactive compounds, and modifications in the sugar also diminished potency. Compounds were also evaluated
in vitro
against the parasites
T. cruzi
,
T. brucei
, and
S. mansoni
, revealing active compounds among this series.
摘要
人们迫切需要更好的药物来防治恰加斯病、非洲昏睡病和血吸虫病,这促使人们寻找克鲁扎因、罗得西亚因和曼氏血吸虫的抑制剂。
曼氏血吸虫
CB1(SmCB1)的抑制剂。
克氏锥虫
,
布氏锥虫
和
曼氏锥虫
和曼森氏杆菌。研究表明,硫代氨基羰基化合物和杂环类似物既能杀灭锥虫,又能抑制寄生虫半胱氨酸蛋白酶。我们合成了一系列化合物,并通过生化试验评估了这些化合物对克鲁沙因、罗得沙因和 SmCB1 的抑制作用,以确定它们的效力和结构-活性关系(SAR)。通过这种方法,发现了 6 种 rhodesain、4 种 cruzain 和 5 种 SmCB1 抑制剂,其 50% 抑制浓度(IC
50
s)≤10 μM。在测试的化合物中,发现过乙酰化半乳糖苷的硫代氨基羰基衍生物(化合物 4i)是一种有效的 rhodesain 抑制剂(IC
50
= 1.2 ± 1.0 μM)。确定了一系列修饰的影响;去除硫代氨基甲酸或用半氨基甲酸取代硫代氨基甲酸会导致化合物几乎失去活性,而糖的修饰也会降低效力。还对化合物进行了
体外
对寄生虫
T. cruzi
,
布鲁氏菌
和
曼森氏杆菌
的活性化合物。